BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
Feb 27, 2012
 |  BioCentury  |  Analyst Picks & Changes

Analyst picks & changes

Analyst picks & changes

Company Bank Analyst Coverage Opinion Wk chg 2/24 cls
Gentium S.p.A. (NASDAQ:GENT) ThinkEquity Mani Mohindru Upgrade Buy (from sell) 1% $8.68
Mohindru also raised his target to $11 from $4 after Gentium submitted responses to Day 120 questions from EMA's CHMP related to the review of defibrotide to treat and prevent hepatic veno-occlusive disease (VOD) in hematopoietic stem-cell transplantation therapy in adults and children (see B13). He believes that the single-stranded oligodeoxyribonucleotides derived from porcine mucosal DNA could be approved in 2012 for at least the prevention indication. The product has Orphan Drug designation in the EU and U.S. to treat and prevent VOD and Fast Track designation in the U.S. to treat VOD.

Read the full 743 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >